Horizon Therapeutics plc (HZNP)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 0 |
| Ownership rank: | -- |
| % of all portfolios: | 0% |
| History | Portfolio Manager | Activity ▼ | Share change | % change to portfolio | |
| Q3 2023 | |||||
| ≡ | David Abrams - Abrams Capital Management | Sell 100.00% | 890,993 | 2.64 | |
| ≡ | Daniel Loeb - Third Point | Sell 100.00% | 500,000 | 0.75 | |
| Q3 2021 | |||||
| ≡ | Viking Global Investors | Sell 100.00% | 1,170,211 | 0.33 | |
| Q2 2021 | |||||
| ≡ | Viking Global Investors | Reduce 44.69% | 945,446 | 0.27 | |
| Q1 2021 | |||||
| ≡ | Viking Global Investors | Reduce 42.24% | 1,547,219 | 0.42 | |
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 1,871 | 0.00 | |
| Q3 2020 | |||||
| ≡ | Viking Global Investors | Reduce 20.23% | 297,675 | 0.08 | |
| Q2 2020 | |||||
| ≡ | Viking Global Investors | Reduce 26.11% | 519,851 | 0.12 | |
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 53,141 | 0.03 | |
| Q1 2020 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 58.30% | 74,295 | 0.04 | |
| Q4 2019 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 23.97% | 40,187 | 0.02 | |
| Q3 2019 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 21.41% | 45,657 | 0.02 | |
| Q1 2019 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 33.55% | 95,660 | 0.04 | |
| Q4 2018 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 4.84% | 14,490 | 0.00 | |
| Q2 2016 | |||||
| ≡ | Stephen Mandel - Lone Pine Capital | Sell 100.00% | 13,997,232 | 1.18 | |
| Q1 2016 | |||||
| ≡ | Stephen Mandel - Lone Pine Capital | Reduce 10.28% | 1,603,756 | 0.14 | |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.